Is it safe?
Can BIIB take a bad year?
Biogen carries $2.01B of net debt at 0.93× EBITDA: a load its earnings can carry.
$2.01B
Net debt · as at Q1 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.93×
Net debt / EBITDA · 1.63× a year ago · the load is coming down
- Interest cover
- 5.90×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 32%
Annualised volatility · about as steady as the market itself
Details›
- Total debtQ1 2026
- $6.29B
- Cash and short-term investments
- $4.28B
- Net debt
- $2.01B
- EBITDA, trailing twelve months
- $2.16B
- Operating profit, trailing twelve months
- $1.62B
- Debt / equity
- 0.34×
- Total debt / EBITDA
- 2.91×
- Annualised volatilitytwo years of daily moves
- 32%
- Worst drawdown on file
- −73%
- Below its 52-week high
- −0.17%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - General
Ranks #12 of 16 by Smart Score